Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology.
At the this year’s edition of the TOP 100 Swiss Startup Award, where Switzerland’s best startups are celebrated, Araris ranks TOP11! What a great success for Araris, after positions 13 in 2020 and 95 in 2019.
We congratulate Philipp Spycher (CEO) and his team for this great achievement!
Araris made it to TOP11 in this year's edition of the TOP 100 Swiss Startup Award.